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Primary hyperparathyroidism is a very rare complication following radioactive iodine therapy. There is typically a latency period
of more than a decade following radiation exposure and, therefore, it is observed almost exclusively in adults. Consequently,
pediatricians are not aware of the association. We present a case of primary hyperparathyroidism due to a solitary parathyroid adenoma occurring in an adolescent male two years following radioactive iodine treatment for papillary thyroid carcinoma. Periodic
screening of serum calcium following ablative doses of radioactive iodine for thyroid cancer may be justified even in adolescents.

1. Introduction
Primary hyperparathyroidism (P-HPT) is uncommon in
children and adolescents with an incidence of 2–5 in
100,000 [1]. Excess parathyroid hormone (PTH) secretion
leads to hypercalcemia, hypophosphatemia, nephrocalcinosis, nephrolithiasis, and decreased bone density. Parathyroid adenoma is the most common cause of P-HPT in
young patients, representing 65–90% of pediatric cases [1–4].
Multiglandular hyperplasia occurs in 16–27% of pediatric PHPT, half of which can be attributable to multiple endocrine
neoplasia (MEN)-I or MEN-II syndromes or familial nonMEN HPT [1, 2]. Due to its rarity in children, most of the
literature on P-HPT in pediatric patients has been limited to
case reports and small series [1–4].
Radioactive iodine treatment (RAI) is an accepted treatment for hyperthyroidism associated with Graves’ disease
and metastatic papillary thyroid carcinoma (PTC) following
surgical resection in adults and children [5, 6]. Colaço et
al. analyzed 47 patients who developed P-HPT following
treatment with RAI for benign and malignant disease [7]. A
female predominance was observed (89.4% women), with PHPT occurring at a mean age of 59.4 ± 13.5 years. The average
latency period to the development of P-HPT after RAI was
13.5 ± 9.1 years. In this review, two patients with Graves’

disease were less than 18 years old (5 and 11 years) at the time
of RAI, and time to development of P-HPT was 31 and 22
years, respectively [8]. Surgical pathology in these individuals
revealed 4-gland hyperplasia in one and an adenoma in the
other. We report a case of a 17-year-old male who presented
with hypercalcemia 2 years following RAI treatment for PTC.
To our knowledge, this is the first patient reported with this
presumed complication of RAI exposure presenting in the
pediatric age range.

2. Case Presentation
A 17-year-old male presented to the pediatric emergency
room with severe headaches. Past medical history was significant for congenital hydrocephalus requiring ventriculoperitoneal shunting and a congenital vein of Galen aneurysm
treated with metal coil embolization in infancy at another
institution. In the course of diagnosis and management of the
hydrocephalus during childhood, he had had 14 computerized tomographic (CT) studies of the brain. At 15 years, he was
diagnosed with PTC metastatic to local lymph nodes in the
right neck that was treated with a total thyroidectomy, neck
dissection, RAI therapy, and L-thyroxine suppression. There
were no postoperative complications. He received two doses
of RAI a year apart, a total of 263 millicuries (mCi). Serum
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thyroglobulin (Tg) level off thyroxine prior to second RAI
treatment was 6.4 ng/mL, while serum thyroid-stimulating
hormone (TSH) was 81 𝜇 IU/mL, suggesting some residual thyroid-like tissue. Post-I131 treatment total body scan
obtained 5 days after the second therapy dose showed uptake
in right neck, interpreted as probable residual thyroid cancer.
Three months after the second RAI dose, he developed severe
headaches and was found to have an intracranial thrombus
of the transverse sinus. At this time, serum calcium was
10 mg/dL and Tg concentration on thyroxine therapy was
<1 ng/mL. He was treated with anticoagulation for one year.
At both 7 and 11 months following the second RAI treatment,
surveillance neck ultrasounds revealed the stable appearance
of a 1 cm nodule in the right thyroid bed that was not
palpable on physical examination. Fine needle aspirate was
planned after stopping anticoagulation therapy. One week
after anticoagulation therapy was discontinued, headaches
acutely returned prompting the emergency room visit. Brain
CT showed progressive, nonocclusive thrombosis of the
transverse sinus. Laboratory studies performed during the
emergency room visit identified hypercalcemia (13.1 mg/dL;
normal range 8.9–10.7) and hypophosphatemia (2 mg/dL;
normal range 3.0–5.2), with a concomitant intact PTH of
154 pg/mL (normal range 9–69). Anticoagulant therapy was
resumed. Neck ultrasound and technetium ( 99m Tc) sestamibi
scan were consistent with a hyperfunctioning right parathyroid adenoma (Figure 1). Prior to proceeding with surgical
excision, recombinant thyrotropin-stimulated serum Tg concentration was <1 ng/mL and total body 4 mCi I 131 scan was
negative. The patient underwent removal of a 1.5 cm right
parathyroid adenoma with benign histology. Fifteen hours
postoperatively, serum PTH and calcium were <3 pg/mL and
9.3 mg/dL, respectively. The patient was transiently treated
with calcium supplementation and remained eucalcemic 2
years following surgery. Follow-up neck ultrasound at 2 years
reveals no nodules.

3. Discussion
Hyperparathyroidism was first reported following external
beam radiation in 1975 and has subsequently been described
following head and neck radiation for benign and malignant
conditions and among atomic bomb survivors of Hiroshima
[9–11]. Cohen et al. evaluated a cohort of 4297 patients who
received radiation to the tonsils before the age of 16 years
and were followed prospectively. The incidence of clinical
hyperparathyroidism was increased approximately 2.5-fold
over the general population and the latency period was 20 to
46 years [12]. McMullen et al. recently reported the incidental
finding of unsuspected hyperparathyroidism largely due to
adenoma in 10% of 53 patients referred for nodular thyroid
disease following radiation for childhood cancer [13]. Latency
period was 15 to 34 years. Estimated radiation exposure to
the neck was 90–1320 centigray (cGy). In the adult literature,
hyperparathyroidism is a rare occurrence following RAI
treatment, which is observed mostly in females and with an
average latency period of 15–20 years following RAI exposure
[7]. Hyperparathyroidism following RAI in pediatric patients
treated for Graves’ disease is reported, but typically occurs
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Figure 1: Ultrasound (a) and technetium ( 99m Tc) sestamibi scan
(b) of nonpalpable 1 cm nodule in right neck prior to removal of
parathyroid adenoma.

during adulthood, more than a decade later [8, 14]. We
found a single report of hyperparathyroidism occurring in a
pediatric thyroid cancer patient at the age of 22 years treated
with 103 mCi of RAI at age 9 years [15]. Hypoparathyroidism
has also been reported following RAI and is usually transient
[16–18].
Estimated dose to the parathyroids following treatment
of Graves’ disease (doses 2–38 mCi) is 140 to 750 cGy [19].
Our patient received a total RAI dose of 263 mci, 10-fold
higher than that typically administered for Graves’ disease.
The incidence of hyperparathyroidism has been suggested
to increase with the dose of radiation exposure [20, 21] and
younger age at exposure [15]. Studies of radiation-exposed
populations have demonstrated a much greater sensitivity to
radiation in children compared with adults, presumably in
part due to greater mutagenic effects of radiation in growing
children’s tissues, which are replicating at a faster rate [22].
Doses as small as 50–100 mGy have been associated with
an increased risk of thyroid malignancy in children, with a
linear dose-response up to about 10–20 Gy after which the
risk appears to level off [23–25]. This excess risk persists for
at least four decades after exposure [23]. Our patient had
numerous CT scans as a young child, estimated to yield a
cumulative exposure of 20–40 cGy to the head in addition to
that from RAI [26]. The contribution of radiation exposure
from early CT scans to our patient’s thyroid cancer and/or
hyperparathyroidism is unclear.
Pediatricians are well aware that hypoparathyroidism is
a known complication of thyroidectomy and thyroid cancer
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surgery. In patients who do not have postoperative hypocalcemia, calcium levels may not subsequently be monitored.
Our patient demonstrates that, while rare, hyperparathyroidism may occur following a short latency period after RAI.
We recommend that serum calcium levels be included in
routine yearly surveillance of these patients, particularly in
those with a history of additional radiation exposure.
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